Pegfilgrastim

Pegfilgrastim
Clinical data
Trade names originally Neulasta, other brand names worldwide[1]
AHFS/Drugs.com Monograph
MedlinePlus a607058
License data
Pregnancy
category
  • US: C (Risk not ruled out)
    ATC code
    Legal status
    Legal status
    Pharmacokinetic data
    Elimination half-life 15–80 hrs
    Identifiers
    CAS Number
    IUPHAR/BPS
    DrugBank
    ChemSpider
    • none
    UNII
    KEGG
    ChEMBL
    ECHA InfoCard 100.169.155 Edit this at Wikidata
    Chemical and physical data
    Formula C845H1343N223O243S9 + PEG
    Molar mass 39,000 g/mol
     ☒N☑Y (what is this?)  (verify)

    Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (GCSF) analog filgrastim. It serves to stimulate the level of white blood cells (neutrophils).[2]

    Pegfilgrastim treatment can be used to stimulate bone marrow to produce more neutrophils to fight infection in patients undergoing chemotherapy.[3]

    Pegfilgrastim has a human half-life of 15 to 80 hours, much longer than the parent filgrastim (3–4 hours).[4][3]

    In the United States as of 2015 the branded form costs between $5,327 and $8,191 a dose.[5]

    As of 9-22-15 a 6 MG/0.6ML dose costs $15,016.29 in the United States.

    Biosimilars

    In July 2016 the US FDA rejected a biosimilar application from Sandoz.[6]

    In 2016 Coherus BioSciences is running clinical studies on its own pegfilgrastim biosimilar CHS-1701.[6]

    References

    1. ↑ Drugs.com International brand names for pegfilgrastim Page accessed April 1, 2016
    2. ↑ Walsh, G, Spada, S. "Epogen/Procrit" in: Directory of approved biopharmaceutical products. CRC Press, 2005, pp. 136–37.
    3. 1 2 Drugs.com: Pegfilgrastim
    4. ↑ Ho, R.J.Y., Gibaldi, M. Biotechnology and biopharmaceuticals: transforming proteins and genes into drugs Wiley-IEEE, 2003, pp. 139, 158.
    5. ↑ Langreth, Robert (June 29, 2016). "Decoding Big Pharma's Secret Drug Pricing Practices". Bloomberg. Retrieved 15 July 2016.
    6. 1 2 US FDA rejects Sandoz’s Neulasta biosimilar. 19 July 2016



    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.